Viking Therapeutics (VKTX) Non-Current Assets (2014 - 2026)
Viking Therapeutics (VKTX) posted Non-Current Assets of $4.3 million for Q2 2026, up 13033.33% sequentially from $33000.0 in Q1 2026, and up 419.66% YoY from $834000.0 in Q2 2025.
Viking Therapeutics (VKTX) Non-Current Assets (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Non-Current Assets for 13 years, with the latest figure at $4.3 million in Q2 2026.
- Quarterly Non-Current Assets rose 419.66% year-over-year to $4.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.2 million (up 25.6% YoY) and the FY2025 annual result came in at $131000.0, down 88.14% from the prior year.
- Non-Current Assets climbed to $4.3 million in Q2 2026 per VKTX's latest filing, from $33000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $4.3 million in Q2 2026 and troughed at $33000.0 in Q1 2026.
- A 5-year average of $1.3 million and a median of $1.3 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets soared 1011.19% in 2022, then tumbled 96.6% in 2026.
- Over 5 years, Non-Current Assets stood at $1.5 million in 2022, then dropped by 15.04% to $1.3 million in 2023, then declined by 12.65% to $1.1 million in 2024, then plunged by 88.14% to $131000.0 in 2025, then soared by 3208.4% to $4.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $4.3 million, $33000.0, and $131000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | 4.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.33 Mn |
| Mar 31, 2026 | 33,000.00 |
| Dec 31, 2025 | 131,000.00 |
| Sep 30, 2025 | 712,000.00 |
| Jun 30, 2025 | 834,000.00 |
| Mar 31, 2025 | 970,000.00 |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.18 Mn |
| Dec 31, 2023 | 1.27 Mn |
| Sep 30, 2023 | 1.36 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Mar 31, 2023 | 1.43 Mn |
| Dec 31, 2022 | 1.49 Mn |
| Sep 30, 2022 | 1.54 Mn |
| Jun 30, 2022 | 1.65 Mn |
| Mar 31, 2022 | 1.73 Mn |
| Dec 31, 2021 | 134,000.00 |
| Sep 30, 2021 | 189,000.00 |